98-92-0 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
107Juvenile idiopathic arthritis2

107. Juvenile idiopathic arthritis


Clinical trials : 447 Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-002245-11-NL
(EUCTR)
16/01/201920/08/2018A study to investigate Vitamin B3 concentrations in the joint after intake Assessing penetration of high dose Nicotinamide (Vitamin B3) in synovial fluid - B-Vit in the joint Juvenile Idiopathic Arthritis (JIA);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: nicotinamide
Product Code: 98-92-0
INN or Proposed INN: NICOTINAMIDE
Other descriptive name: Vitamin B3
UMC UtrechtNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
6 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noNetherlands
2EUCTR2016-003643-10-NL
(EUCTR)
14/09/2017A study to investigate the safety of additional treatment with Vitamin B3 in children with Juvenile Idiopathic Arthritis (JIA)Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment - B-Vit in JIA Juvenile idiopathic arthritis (JIA);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: nicotinamide
Product Code: 98-92-0
UMC UtrechtNULLNAFemale: yes
Male: yes
Phase 1;Phase 2Netherlands